Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference
Personalis (Nasdaq: PSNL), a leading company in advanced genomics for precision oncology, has announced its management team's upcoming participation in the 24th Annual Needham Virtual Healthcare Conference. The event is scheduled for Wednesday, April 9, 2025.
Personalis (Nasdaq: PSNL), un'azienda leader nella genomica avanzata per l'oncologia di precisione, ha annunciato la prossima partecipazione del suo team di gestione alla 24ª Conferenza Virtuale Annuale di Needham sulla Salute. L'evento è programmato per mercoledì 9 aprile 2025.
Personalis (Nasdaq: PSNL), una empresa líder en genómica avanzada para la oncología de precisión, ha anunciado la próxima participación de su equipo directivo en la 24ª Conferencia Virtual Anual de Salud de Needham. El evento está programado para miércoles 9 de abril de 2025.
Personalis (Nasdaq: PSNL), 정밀 종양학을 위한 고급 유전체학의 선두 기업이, 제24회 니드햄 가상 의료 회의에 경영진이 참여할 예정이라고 발표했습니다. 이 행사는 2025년 4월 9일 수요일에 예정되어 있습니다.
Personalis (Nasdaq: PSNL), une entreprise leader en génomique avancée pour l'oncologie de précision, a annoncé la prochaine participation de son équipe de direction à la 24e Conférence Virtuelle Annuelle de Needham sur la Santé. L'événement est prévu pour mercredi 9 avril 2025.
Personalis (Nasdaq: PSNL), ein führendes Unternehmen in der fortgeschrittenen Genomik für präzise Onkologie, hat die bevorstehende Teilnahme seines Management-Teams an der 24. jährlichen virtuellen Gesundheitskonferenz von Needham angekündigt. Die Veranstaltung ist für Mittwoch, den 9. April 2025 geplant.
- None.
- None.
About Personalis, Inc.
At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250326149116/en/
Investors:
Caroline Corner
investors@personalis.com
415-202-5678
Media:
pr@personalis.com
Source: Personalis, Inc.
FAQ
When is Personalis (PSNL) presenting at the Needham Healthcare Conference 2025?
What type of company is Personalis (PSNL)?
Is the 2025 Needham Healthcare Conference virtual or in-person?
Which stock exchange is Personalis traded on?
